Stadiul cunoaşterii.... - Gr.T. Popa

Corelaţii clinice,imunohistochimice şi morfopatologice în unele tumori de ovar
Coordonator ştiinţific:Prof.Dr.Zenovia Florentina Pricop
__________________________________________________Doctorand:Ioana Buda
75. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA 1996; 65:5-27.
76. Parker, D., Bradley, C., Bogle, S. M., Lay, J., Masood, M., Hancock, A. K. et al. (1994). Serum albumin and
CA125 are powerful predictors of survival in epithelial ovarian cancer. Br. J. Obstet. Gynaecol. 101(10), 888–
893.
77. Pautier P, Lhomme C, Culine S, et al. Adult granulosa cell tumor of the ovary: a retrospective study of 45 cases.
Int J Gynecol Cancer 1997;7:58–65
78. Pearl, M. L., Yashar, C. M., Johnston, C. M., Reynolds, R. K., and Roberts, J. A. (1994). Exponential regression
of CA 125 during salvage treatment of ovarian cancer with taxol. Gynecol. Oncol. 53(3), 339–343.
79. Powell JL, Otis CN. Management of advanced juvenile granulosa cell tumor of the ovary. Gynecol Oncol. Feb
1997;64(2):282-4.
80. Prat J., Matias-Guiu X., Barreto J., Simultaneous carcinoma involving the endometrium and the ovary: a
clinicopathologic, immunohistochemical, and DNA flow cytometric study of 18 cases, Cancer, 1991, 68: 2455-
2459
81. Pricop M., Oncologie ginecologică clinică, Editura Polirom, Iaşi, 2000
82. Pricop M.,Chirurgie ginecologica.Puncte de vedere,Institutul European,2006 125-133
83. Pricop M.Curs de obstetrica si ginecologie ,Institutul European 2001,Volumul 2-Ginecologia 267-296
84. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, et al. Mutant ras oncogenes upregulate
VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res
1995;55:4575–80.
85. Rubin SC, Sabbatini P, Randall ME. Ovarian Cancer. In: Pazdur R, Hoskins WH, Wagman L, eds. Cancer
Management: A Multidisciplinary Approach. 4th ed. Mellville, NY: PRR Incorporated; 2000:. 409-28.
86. Sadler T.W,Embriologie medicala,Callisto ,2007
87. Sakaki M, Hirokawa M, Horiguchi H, Wakatsuki S, Sano T, Izumi Y: Ovarian fibrothecoma with massive
edema. J Med Invest 2000, 47:148-150
88. Skirnisdóttir I, Seidal T, Gerdin E, sorbe B – The prognostic importance of p53, Bcl-2, and Bax in early stage
epithelial ovarian carcinoma treated with adjuvant chemotHERapy, Int J Gynecol Cancer, 2002, 12(3):265-276
89. Slamon D J. Godolphin W, Jones LA el al. Studies of the HER-2, neu proto-oncogene in human breast and
ovarian cancer. Science 1989: 244:707 712
90. Slotman BJ & Rao BR 1988 Ovarian cancer (review): etiology, diagnosis, prognosis, surgery, radiotHERapy,
chemotHERapy and endocrine tHERapy. Anticancer Research 8 417–434. Endocrine-Related Cancer (2000) 7
85–93
91. Surcel I.V.-Obstetrica si ginecologie,Dacia ,2005,925-939
92. Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM, 2006b. Cytokeratins 7 and 20 in primary and
secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and
staining distribution in 174 cases. Am J Surg Pathol. 30(9):1130-1139).-
93. Vermorken JB, Parmar MKB, Brady MF – Clinical trials in ovarian carcinoma: study methodology, Ann Oncol,
2005;16:20-29
94. Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, et al. Expression of the vascular
endothelial growth factor (VEGF) in epithelial ovarian neoplasm: correlation with clinicopathology and patients
survival, and analysis of serum VEGF levels. Br J Cancer 1997;76:1221–7.
80